Loxoribine
Alternative Names: RWJ 21757Latest Information Update: 08 Jun 2001
At a glance
- Originator Johnson & Johnson
- Developer Johnson & Johnson; Nonindustrial source
- Class Antineoplastics; Purine nucleosides; Small molecules
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Endometriosis
- Discontinued Cancer